

OIE Reference Laboratory Reports Activities

Activities in 2019

This report has been submitted : 2020-01-13 17:49:48

Name of disease (or topic) for which you are a designated OIE Reference Laboratory:	Contagious caprine pleuropneumonia
Address of laboratory:	Campus International de Baillarguet TA A117/E 34398 Montpellier cedex 5 FRANCE
Tel.:	+33 (0)4 67 59 37 24
Fax:	+33 (0)4 67 59 37 98
E-mail address:	francois.thiaucourt@cirad.fr
Website:	https://umr-astre.cirad.fr/
Name (including Title) of Head of Laboratory (Responsible Official):	Nathalie Vachier Directrice unité ASTRE
Name (including Title and Position) of OIE Reference Expert:	François Thiaucourt Responsable des laboratoires de référence PPCB/PPCC
Which of the following defines your laboratory? Check all that apply:	Governmental Research

ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests		Nationally	Internationally
cELISA	oui	0	300
Direct diagnostic tests		Nationally	Internationally
isolement	oui	0	10
PCR	Oui	0	5

**ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.
To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.**

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient OIE Member Countries	Region of recipients
antigène	cELISA	0	0	20	1	<input type="checkbox"/> Africa <input type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East
milieu de culture contrôlé	isolement	0	0	10		<input checked="" type="checkbox"/> Africa <input type="checkbox"/> Americas <input checked="" type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East

4. Did your laboratory produce vaccines?

Yes

5. Did your laboratory supply vaccines to OIE Member Countries?

Yes

Vaccine name	Amount supplied nationally (ml, mg) (including for own use)	Amount supplied to other countries (ml, mg)	Name of recipient OIE Member Countries
Adjuvant saponine pour vaccin inactivé	0	2mg	SWITZERLAND
Vaccin inactivé contre la PPCC	0	100 doses	UNITED ARAB EMIRATES

ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

Yes

Name of OIE Member Country seeking assistance	Date (month)	No. samples received for provision of diagnostic support	No. samples received for provision of confirmatory diagnoses
NIGER	8	0	5
KENYA	9	80	0

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

Yes

Name of the OIE Member Country receiving a technical consultancy	Purpose	How the advice was provided
BURUNDI	suivi campagne contrôle de la PPR et évaluation risque PPCC	Visite sur place à Bujumbura
SAUDI ARABIA	présentation de la PPCC et des stratégies de lutte	Enseignement et conférence à l'Université King Faisal

ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

Yes

Title of the study	Duration	Purpose of the study	Partners (Institutions)	OIE Member Countries involved other than your country
Projet Multivac	3	développer des vaccins multivalents	IDRC	NIGER

ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:
Séquençage de génomes complets de souches de <i>Mycoplasma capricolum</i> subsp. <i>capripneumoniae</i>

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

No

If the answer is no, please provide a brief explanation of the situation:
Données en cours d'analyse et à publier en 2020

13. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category)

a) Articles published in peer-reviewed journals: 1

Ganter, S., Miotello, G., Manso-Silvan, L., Armengaud, J., Tardy, F., Gaurivaud, P., and Thiaucourt, F. (2019). Proteases as Secreted Exoproteins in Mycoplasmas from Ruminant Lungs and Their Impact on Surface-Exposed Proteins. *Applied and Environmental Microbiology* 85, e01439-01419.

b) International conferences: 2

1) La PPCC et ses strategies de lutte. Arabie Saoudite Mars 2019 5 jours

2) Conference FEMS Londres Mars 2019 2 jours

c) National conferences: 1

Conference regionale sur les analyses proteomiques. Montpellier 19 et 20 Decembre 2019: Application de la proteomique au controle qualite de vaccins inactives PPCC

d) Other:

(Provide website address or link to appropriate information) 1

Manso-Silvan, L., and Thiaucourt, F. (2019). Contagious caprine pleuropneumonia. In *Transboundary Animal Diseases in Sahelian Africa and Connected Regions*. M. Kardjadj, A. Diallo, and R. Lancelot, eds. (Switzerland: Springer Nature Switzerland), pp. 439-458.

ToR 7: To provide scientific and technical training for personnel from OIE Member Countries

To recommend the prescribed and alternative tests or vaccines as OIE Standards

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

Yes

- a) Technical visits: 1
 b) Seminars: 0
 c) Hands-on training courses: 0
 d) Internships (>1 month): 0

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
a: diagnostic PPCC	Kenya	5

ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
ISO 17025	attestation accreditation 1-2207.pdf

16. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
ELISA (portée flexible)	COFRAC

17. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

(See *Manual of Diagnostic Tests and Vaccines for Terrestrial Animals*, Chapter 1.1.4)

ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

Yes

National/ International	Title of event	Co-organiser	Date (mm/yy)	Location	No. Participants
1	Comité de pilotage du projet Multivac	0	9/19	Nairobi	15

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

Yes

Title of event	Date (mm/yy)	Location	Role (speaker, presenting poster, short communications)	Title of the work presented
Conférence nationale sur la lutte contre la PPR	05/2019	Bujumbura	orateur	Après la PPR, le risque PPCC pour le Burundi

ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Not applicable (Only OIE Reference Lab. designated for disease)

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

Not applicable (Only OIE Reference Lab. designated for disease)

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Not applicable (Only OIE Reference Lab. designated for disease)

ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

Yes

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at:
<http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing> see point 1.3

Purpose for inter-laboratory test comparisons ¹	No. participating laboratories	Region(s) of participating OIE Member Countries
Validation de compétence pour la réalisation des cELISA	4	<input checked="" type="checkbox"/> Africa <input type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East
Validation de la détection par PCR	4	<input checked="" type="checkbox"/> Africa <input type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East

ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE?

Yes

Kind of consultancy	Location	Subject (facultative)
révision des chapitres PPCC du manuel des standards ainsi que du code sanitaire	Montpellier	Réviser et actualiser les textes.

25. Additional comments regarding your report:

Notre laboratoire continue de valider l'ensemble des lots de kits cELISA produits par la société IDEXX afin de garantir leur conformité avant mise sur le marché.
 Cette activité est fondamentale pour garantir la fiabilité des résultats sérologiques générés et les informations épidémiologiques transmises (réduction de l'incertitude de mesure, maintien de la spécificité du test).

Il faut noter que l'activité de labo de référence est de plus en plus difficile du fait du coût de transport des échantillons, ainsi que de la complexité administrative (respect des protocoles de Nagoya)